The Effects of Intravenous Heme Arginate on Heme Oxygenase-1 Expression (HO-1) and Oxidative Stress in the Human Heart
Status:
Completed
Trial end date:
2017-06-13
Target enrollment:
Participant gender:
Summary
Ischemia reperfusion injury may be attenuated by HO-1 induction. Our previous data confirmed
strong HO-1 induction in peripheral blood cells following heme arginate infusion in healthy
humans. Furthermore, we could demonstrate the amelioration of experimental ischemia
reperfusion injury in the calf musculature by heme arginate in healthy subjects as measured
by functional MRI.
Therefore, we propose that HO-1 induction in the human heart may be a suitable target to
mitigate cardiac ischemia-reperfusion injury.
The HO-1 induction will be assessed in a clinical trial by myocardial biopsy prior to and
after aortic cross-clamping in subjects with or without preceding heme arginate treatment in
two different dosages. The HO-1 expression will also be measured in the clinical trials in
peripheral blood mononuclear cells. As additional outcome, levels of myoglobin,
creatine-kinase and troponin T and reactive oxygen species will be measured in plasma
according to standard laboratory procedures.